Continued Success in Helping our Clients Obtain Strong Patent Protection.
More than any other industry, the innovative pharmaceutical industry depends on strong patent protection to continue bringing valuable products to market. Milbank's pharmaceutical patent attorneys pride themselves on numerous successes – both high profile and behind the scenes – in helping clients protect their most valued drugs throughout the products’ life, in and out of court.
A Broad Spectrum of Expertise and Experience
Our attorneys handle all types of pharmaceutical IP litigation, including Hatch-Waxman Act and multi-party litigation. We are also thoroughly versed and prepared to counsel and represent companies in biosimilar litigation. We have also settled numerous Hatch-Waxman Act cases in a manner satisfactory to competition authorities. In addition to litigation, we have extensive expertise in complex licensing of patented technology, counseling, patent prosecution and interferences, pre-litigation and M&A IP due diligence experience for the chemistry, pharmaceutical and biotechnology industries.
Our areas of expertise include all types of pharmaceuticals, proteomics, pharmacogenomics, diagnostics, therapeutics, drug design, bioinformatics and medical devices as well as the traditional areas of organic and inorganic chemistry.
Attorneys in our pharmaceutical IP practice have diverse backgrounds and most have technical degrees in areas such as chemistry, biology, biochemistry and chemical engineering as well as extensive practical experience in all aspects of life sciences.
Our pharmaceutical patent attorneys have been acknowledged by The National Law Journal as among the nation’s top trial lawyers and recognized in Chambers USA for Intellectual Property. Our publications have been cited by courts, recognized nationwide, and bestowed the "Burton Award for Best Law Firm Publication".
A Team Approach
We strive to serve as an extension of inside counsel by dedicating a lean group of attorneys to our clients and their matters. We consider it our shared responsibility to diligently and efficiently prepare in advance for challenges, whether they be generic ANDA or non-generic, so that together we can shepherd our client’s drug through the minefield of challenges while maintaining hard-earned exclusivity.